Lindi Campbell, founder of Breath of Hope KY, participates as a patient panelist in a Lung Cancer Social Media CME program discussion. Lindi is now on a newly approve targeted therapy drug, Osimertinib, for her lung cancer recurrence of early-stage lung cancer. She was asked to participate in this panel discussion with a group of medical professionals to give her input and opinion on this new treatment option recently approved by the FDA for early-stage lung cancer patients. This newly approved drug now gives a promising outlook in delaying or possibly preventing another recurrence of Lindi’s lung cancer.
